J. B. Chemicals & Pharmaceuticals Management
Management criteria checks 3/4
J. B. Chemicals & Pharmaceuticals' CEO is Nikhil Chopra, appointed in Dec 2020, has a tenure of 4.17 years. total yearly compensation is ₹71.34M, comprised of 49.2% salary and 50.8% bonuses, including company stock and options. directly owns 0.032% of the company’s shares, worth ₹85.91M. The average tenure of the management team and the board of directors is 2 years and 4.3 years respectively.
Key information
Nikhil Chopra
Chief executive officer
₹71.3m
Total compensation
| CEO salary percentage | 49.2% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 07
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Share Price Could Signal Some Risk
Jan 29We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 27J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 09J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹6b |
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹71m | ₹35m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹65m | ₹37m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹59m | ₹18m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹5b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹32m | ₹7m | ₹4b |
Compensation vs Market: Nikhil's total compensation ($USD814.61K) is above average for companies of similar size in the Indian market ($USD558.05K).
Compensation vs Earnings: Nikhil's compensation has been consistent with company performance over the past year.
CEO
Nikhil Chopra (51 yo)
4.2yrs
Tenure
₹71,338,000
Compensation
Mr. Nikhil Ashokkumar Chopra serves as Chief Executive Officer and Whole-Time Director at J. B. Chemicals & Pharmaceuticals Limited since December 23, 2020 and has been its Director since May 10, 2020. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Whole-Time Director | 4.2yrs | ₹71.34m | 0.032% ₹ 85.9m | |
| Assistant Vice President – Human Resource | no data | ₹10.48m | 0.0010% ₹ 2.8m | |
| Chief Financial Officer | 1yr | ₹12.74m | no data | |
| President of Operations | no data | ₹28.44m | 0.016% ₹ 43.0m | |
| Vice President of Finance & Accounts | no data | ₹9.48m | no data | |
| Vice President of Information & Technology | 10yrs | ₹10.70m | no data | |
| Vice President of HR & Administration | 8.4yrs | ₹13.80m | 0.00084% ₹ 2.2m | |
| Vice President of Legal | 2yrs | ₹11.49m | no data | |
| President of Global Business | no data | ₹42.09m | 0.0039% ₹ 10.3m | |
| Executive Vice President of Operations of Daman | 1.5yrs | ₹17.24m | 0.0077% ₹ 20.6m | |
| Executive Vice President of Supply Chain Operations | no data | ₹19.54m | 0.0032% ₹ 8.6m | |
| Executive Vice President | 1.1yrs | ₹18.12m | 0.0046% ₹ 12.4m |
2.0yrs
Average Tenure
51yo
Average Age
Experienced Management: JBCHEPHARM's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Whole-Time Director | 4.3yrs | ₹71.34m | 0.032% ₹ 85.9m | |
| Chairman of Biotech Laboratories (Pty ) Ltd | no data | no data | no data | |
| Non-Executive Independent Chairman | less than a year | no data | no data | |
| Non-Executive & Independent Director | 4.5yrs | ₹7.50m | no data | |
| Non-Executive Director | 4.5yrs | no data | no data | |
| Non-Executive & Non-Independent Director | 1.3yrs | no data | no data | |
| Non-Executive Director | 4yrs | no data | no data | |
| Non-Executive & Independent Director | 4.5yrs | ₹7.50m | no data |
4.3yrs
Average Tenure
64.5yo
Average Age
Experienced Board: JBCHEPHARM's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 07:17 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
J. B. Chemicals & Pharmaceuticals Limited is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| null null | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |